СОВРЕМЕННЫЕ ПОДХОДЫ В ЛЕЧЕНИИ МЕСТНОРАСПРОСТРАНЕННОГО РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ

Алексеев Б.Я. и др. Клинические рекомендации по диагностике и лечению больных раком предстательной железы//общероссийский союз общественных объединений ассоциация онкологов россии. -2014. -С. 307-608.

Чиссов В.И., Русаков И.Г. Заболеваемость раком предстательной железы в российской Федерации//Экспериментальная и клиническая урология. -2011. -№. 2-3. -С. 6-7.

Широкорад В.И. и др. Методы диагностики местнораспространенного рака предстательной железы (обзор литературы)//Вестник российского государственного медицинского университета. -2014. -№. 1.

Bekelman J.E. et al. Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer//Journal of Clinical oncology. -2015. -Vol. 33. -№. 7. -P 716-722.

Bolla M. et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin//New England Journal of Medicine. -1997. -Vol. 337. -№. 5. -P 295-300.

Bolla M. et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)//The Lancet. -2005. -Vol. 366. -№. 9485. -P. 572-578.

Briganti A. et al. Pelvic lymph node dissection in prostate cancer//european urology. -2009. -Vol. 55. -№. 6. -P 1251-1265.

Brundage M. et al. Impact of radiotherapy when added to androgen-deprivation therapy for locally advanced prostate cancer: long-term quality-of-life outcomes from the NCIC CTG PR3/MRC PR07 randomized trial//Journal of Clinical oncology. -2015. -Vol. 33. -№. 19. -P. 2151-2157.

Carver B.S. et al. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer//The Journal of urology. -2006. -Vol. 176. -№. 2. -P 564-568.

Daskivich T.J. et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a US population-based cohort of men with prostate cancer//Annals of internal medicine. -2013. -Vol. 158. -№. 10. -P. 709-717.

Ferlay J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012//International journal of cancer. -2015. -Vol. 136. -№. 5.

Fizazi K. et al. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG

trial//European Journal of Cancer. -2012. -Vol.48. -№. 2. -P. 209-217.

Freedland S. J. et al. Radical prostatectomy for clinical stage T3a disease//Cancer. -2007. -Vol. 109. -№. 7. -P 1273-1278.

Gerber G.S. et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis//European urology. -1997. -Vol. 32. -№. 4. -P. 385-390.

Gillessen S. et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015//Annals of Oncology. -2015. -Vol. 26. -№. 8. -P 1589-1604.

Gnanapragasam V. J. et al. The role of surgery in high risk localised prostate cancer//BJU international. -2012. -Vol. 109. -№. 5. -P 648-658.

Gontero P. et al. Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study//European urology. -2007. -Vol. 51. -№. 4. -P. 922-930.

Heidenreich A. et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer//European urology. -2014. -Vol. 65. -№. 2. -P 467-479.

Heidenreich A., Ohlmann C.H. The role of anatomic extented pelvic lymphadenectomy in men undergoing radical prostatectomy for prostate cancer//EAU Update Series. -2005. -Vol. 3. -№. 2. -P 98-106.

Heidenreich A., Varga Z., Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis//The Journal of urology. -2002. -Vol. 167. -№. 4. -P. 1681-1686.

Hemminki K. Familial risk and familial survival in prostate cancer//World journal of urology. -2012. -Vol. 30. -№. 2. -P. 143-148.

Hsu C. Y. et al. Prognostic factors for and outcome of locally advanced prostate cancer after radical prostatectomy//BJU international. -2010. -Vol. 105. -№. 11. -P. 1536-1540.

Jansson K. F. et al. Concordance of tumor differentiation among brothers with prostate cancer//European urology. -2012. -Vol. 62. -№. 4. -P 656-661.

Keane T. et al. Treatment options in prostate cancer once primary therapy fails//European urology supplements. -2007. -Vol. 6. -№. 3. -P 344-353.

Klein E. A. et al. Locally advanced prostate cancer//Current treatment options in oncology. -2001. -Vol. 2. -№. 5. -P 403-411.

Leibel S. A. et al. The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement//International Journal of Radiation Oncology* Biology* Physics. -1994. -Vol. 28. -№. 1. -P. 7-16.

Loeb S. et al. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer//Urology. -2007. -Vol. 69. -№. 6. -P 1170-1175.

Lou D. Y., Fong L. Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor//Urologic Oncology: Seminars and Original Investigations. -Elsevier, 2016. -Vol. 34. -№. 4. -P 182-192.

Lu-Yao G. L. et al. Outcomes of localized prostate cancer following conservative management//Jama. -2009. -Vol. 302. -№. 11. -P. 1202-1209.

Mason M. D. et al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer//Journal of Clinical Oncology. -2015. -Vol. 33. -№. 19. -P. 2143-2150.

Messing E. M. et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy//The lancet oncology. -2006. -Vol. 7. -№. 6. -P. 472-479.

Moschini M. et al. Outcomes for patients with clinical lymphadenopathy treated with radical prostatectomy//European urology. -2016. -Vol. 69. -№. 2. -P 193196.

Mottet N. et al. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial//European urology. -2012. -Vol. 62. -№. 2. -P. 213-219.

Mottet N. et al. Prostate cancer guidelines URL: http://uroweb.org/guideline/prostate-can-cer/2017.

Nazim S. M., Abbas F. Role of Surgery in locally advanced prostate cancer//Pakistan journal of medical sciences. -2015. -Vol. 31. -№. 3. -P. 710.

Schutz F.A.B., Oh W.K. Neoadjuvant and adjuvant therapies in prostate cancer//Urologic Clinics of North America. -2010. -Vol. 37. -№. 1. -P 97-104.

Siddiqui S. A. et al. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study//The Journal of urology. -2008. -Vol. 179. -№. 5. -P 1830-1837.

Stephenson A.J. et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition//Journal of Clinical Oncology. -2006. -Vol. 24. -№. 24. -P 3973-3978.

Thompson I. M. et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial//Jama. -2006. -Vol. 296. -№. 19. -P 2329-2335.

van den Ouden D., Hop W. C. J., Schroder F. H. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy//The Journal of urology. -1998. -Vol. 160. -№. 4. -P. 1392-1397.

Van Poppel H. et al. Radical Prostatectomy Can Provide a Cure For Well-Selected Clinical Stage T3 Prostate Cancer//European urology. -2000. -Vol. 38. -№. 4. -P 372-379.

Van Poppel H. et al. Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001)//European Journal of Cancer. -2006. -Vol. 42. -№. 8. -P. 1062-1067.

Van Poppel H. Neoadjuvant hormone therapy and radical prostatectomy: the jury is still out//European urology. -2001. -Vol. 39. -№. Suppl. 1. -P. 10-14.

Van Poppel H., Joniau S., Haustermans K. Surgery alone for advanced prostate cancer?//European Journal of Cancer Supplements. -2007. -Vol. 5. -№. 5. -P 157169.

Ward J. F. et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate specific antigen testing: 15 year outcome//BJU international. -2005. -Vol. 95. -№. 6. -P 751-756.

Widmark A. et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial//The Lancet. -2009. -Vol. 373. -№. 9660. -P 301-308.

Xylinas E. et al. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single centre experience//BJU international. -2009. -Vol. 103. -№. 9. -P. 1173-1178.

Xylinas E., Dach A., Rouprt M. Is radical prostatectomy a viable therapeutic option in clinically locally advanced (cT3) prostate cancer?//BJU international. -2010. -Vol. 106. -№. 11. -P 1596-1600.

Yamamoto Y. et al. Risk factors of recurrence after radical prostatectomy for locally advanced prostate cancer//Nihon Hinyokika Gakkai zasshi. The japanese journal of urology. -2014. -Vol. 105. -№. 3. -P. 91-96.

Yuh B. et al. The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: a systematic review//European urology. -2014. -Vol. 65. -№. 5. -P 918927.